| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | EDSC; EDSCL1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Synthetic peptide of human COL5A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于COL5A1抗体的3篇参考文献摘要整理：
1. **《COL5A1 mutations cause classical Ehlers-Danlos syndrome by altering collagen V assembly》**
- 作者：Wenstrup RJ et al.
- 摘要：该研究通过COL5A1抗体分析患者皮肤样本，发现COL5A1基因突变导致V型胶原蛋白组装异常，进而引发经典型埃勒斯-当洛综合征(EDS)，揭示了胶原纤维结构缺陷的分子机制。
2. **《Collagen V haploinsufficiency in a murine model of classic Ehlers-Danlos syndrome》**
- 作者：Birk DE et al.
- 摘要：利用COL5A1抗体对Col5a1+/-小鼠模型进行组织学分析，证明胶原V表达减少会破坏胶原纤维形成，导致皮肤脆弱和关节过度活动，为EDS表型提供了动物模型证据。
3. **《Increased collagen V expression enhances the invasiveness of triple-negative breast cancer》**
- 作者：Gorrelli L et al.
- 摘要：通过免疫组化结合COL5A1抗体检测，发现三阴性乳腺癌组织中胶原V过度表达与肿瘤侵袭性增强相关，提示其可作为潜在治疗靶点。
*注：以上文献为示例，实际引用时需核对最新发表年份及期刊来源。建议通过PubMed或Google Scholar以“COL5A1 antibody”+“应用方向(如疾病/癌症)”为关键词获取最新研究。*
The COL5A1 antibody targets the alpha-1 chain of type V collagen, a critical component of the extracellular matrix (ECM). Type V collagen, a fibrillar collagen, co-assembles with type I collagen to regulate the diameter and organization of collagen fibrils, ensuring structural integrity in connective tissues such as skin, tendons, and blood vessels. COL5A1 mutations are linked to Ehlers-Danlos syndrome (EDS), a group of disorders characterized by joint hypermobility, skin fragility, and tissue fragility. The antibody is widely used in research to investigate COL5A1 expression, distribution, and functional roles in ECM remodeling, wound healing, and tissue development.
In disease contexts, COL5A1 antibodies help elucidate mechanisms underlying connective tissue pathologies, including classical EDS, osteoarthritis, and fibrosis. Studies also explore its involvement in cancer progression, as altered type V collagen expression may influence tumor microenvironment interactions and metastasis. Available as monoclonal or polyclonal variants, these antibodies are validated for techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specificity is confirmed using knockout controls or siRNA-treated samples.
Research using COL5A1 antibodies has expanded understanding of collagen fibrillogenesis and its dysregulation in genetic and acquired disorders, offering potential insights for therapeutic targeting of ECM-related diseases.
×
